Interestingly, due to somatic GATA1 mutations that occur in younger DS patients, outcomes in PED ML-DS (especially those <2 years of age) are superior to those without DS, mainly due to increased chemosensitivity [8]. The gene discussed is GATA1; the disease is Dravet syndrome.